Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: kinase inhibitors - Daiichi Sankyo/Teva Pharmaceutical Industries

Drug Profile

Research programme: kinase inhibitors - Daiichi Sankyo/Teva Pharmaceutical Industries

Alternative Names: CEP-17940; CEP-18050; CEP-28122; CEP-31933; CEP-40783; CEP-4416; CEP-7055; CEP-A; RXDX-106

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambit Biosciences Corporation; Cephalon
  • Developer Daiichi Sankyo Company; Ignyta; Teva Pharmaceutical Industries
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Axl receptor tyrosine kinase inhibitors; Proto oncogene protein b raf inhibitors; Proto oncogene protein c met inhibitors; Proto-oncogene protein c-mer inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 29 Dec 2017 US FDA approves IND application for RXDX 106 in Solid tumours (Late-stage disease, Metastatic disease)
  • 10 Nov 2017 Preclinical development is ongoing in USA
  • 08 Nov 2017 Ignyta plans the phase I TITAN trial of RXDX 106 for Solid tumours (Late-stage disease; Metastatic disease; Second-line treatment or greater) (NCT03454243)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top